Plain-English translation of NCT03892993 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers at M.D. Anderson Cancer Center are building a new decision-making tool to help people with medullary thyroid cancer and their caregivers work with their doctors to choose the best path forward. The tool is designed to support conversations about whether to start a new medication, stop treatment, join a clinical trial, or continue watching the cancer carefully without immediate treatment. This study will gather feedback from patients, family members, and doctors to make sure the tool is easy to understand and actually helpful in real life.
Many people with medullary thyroid cancer face complex decisions that can feel overwhelming, and doctors and patients don't always have clear guidance on the best way to make these choices together. This study aims to create a practical tool that brings patients' values and concerns into the conversation with their care team, making these difficult decisions less stressful and more informed.
You likely qualify if…
You likely don't qualify if…
Your involvement would be straightforward: you would use the new decision-making tool and then complete a questionnaire to share your thoughts about whether it was helpful, easy to understand, and practical for your situation. The study is looking for feedback from patients, family members, and healthcare providers to make sure the tool works well in real clinical settings. There is no specific time commitment mentioned, but participation should take a reasonable amount of time to use the tool and answer questions about your experience.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States